Development of Cancer Screening

Development of a universal cancer test based on the EDIM technology using the markers TKTL1 and Apo10

In cooperation with

Clinic for Internal Medicine at the Hochwaldkrankenhaus Bad Nauheim + Hospital Northwest Frankfurt

MEANING OF CANCER SCREENING

Cancer can affect everyone; the statistics show that almost every second person is confronted with cancer. The likelihood that it affects a person or an important person in a family or circle of friends is very great.

There are various causes for the development of cancer. Life style and nutrition play a key role here, but other factors that cannot be influenced personally, such as exposure to environmental toxins, genetic predisposition or chronic inflammation, can also be responsible for the development of cancer.

Cancer can be treated successfully if it is detected early. The ideal is if it can be completely removed surgically before it grows invasively and forms metastases. As soon as metastases have formed, the disease is considered non-curable with orthodox medicine. Therapies are then only aimed at improving the quality of life and extending life. Approximately 50% of the tumour diseases are fatal, which means that the proportion of tumours not detected in time is quite high.

The disease cancer in itself is not the real problem, but late detection of the cancer.

THERE IS NO SAFE PROTECTION AGAINST CANCER, EVENTHOUGH HEALTHY NUTRITION AND A HEALTHY LIFE STYLE CAN REDUCE THE CHANCE OF DEVELOPING CANCER: THEREFORE, THE OBJECTIVE MUST BE TO DETECT A POSSIBLE CANCER EARLY SO THAT IT CAN BE SUCCESSFULLY TREATED.

The forthcoming EDIM detect recognises tumours, regardless of the tumour entity. It can be carried out very simply and is comparatively cost effective. A blood sampling is sufficient for the examination and can be carried out by every general practitioner. The examination itself takes place in specialised laboratories.

This simplicity and the favourable price make it possible to carry out the test once a year!

Such a procedure increases the chances of discovering a tumour at a very early stage, thus increasing the chances of healing.

USED BIOMARKER TKTL1 AND APO10:

In the EDIM detect, the markers TKTL1 and Apo10 are used.

Both biomarkers detect fundamental biophysical mechanisms that are significantly altered in all forms of malignancy (Grimm et al., 2013).

  • Grimm, M.; Schmitt, S.; Teriete, P.; Biegner, T.; Stenzl, A.; Hennenlotter, J.; Muhs, H.J.; Munz, A.; Nadtotschi, T.; König, K.; et al.
    A biomarker based detection and characterization of carcinomas exploiting two fundamental biophysical mechanisms in mammalian cells.
    BMC Cancer 2013, 13, 569. [PubMed]

All forms of tumour cells exhibit a disorder in the process of the planned cell death (apoptosis). Only when this process is disturbed and as a result of which the cell no longer kills itself can a tumour cell form. This apoptosis can be detected with Apo10.

TKTL1 shows the change of energy generation from oxidative phosphorylation to fermentative energy release. This is also a fundamental biophysical process that can be used by all tumour cells, regardless of their entity. The activation of the TKTL1 gene in tumour cells leads to a fermentative, oxygen-independent metabolism which is accompanied by an increased uptake of glucose, an enhanced formation of lactic acid and the capacity for invasive growth.

The meaning and function of TKTL1 has been clearly demonstrated with the latest publication:

  • Jayachandran, A.; Lo, P.H.; Chueh, A.C.; Prithviraj, P.; Molania, R.; Davalos-Salas, M.; Anaka, M.; Walkiewicz, M.; Cebon, J.; Behren, A.
    Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells.
    BMC Cancer 2016, 16, 134. [PubMed]
  • Diaz-Moralli, S.; Aguilar, E.; Marin, S.; Coy, J.F.; Dewerchin, M.; Antoniewicz, M.R.; Meca-Cortés, O.; Notebaert, L.; Ghesquière, B.; Eelen, G.; et al.
    A key role for Transketolase-like 1 in tumor metabolic reprogramming.
    Oncotarget 2016, 7, 51875–51897 [PubMed]